Drugs / FT576
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05182073 | Nov 2021 → Sep 2024 | plasma cell myeloma | Fate Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT576 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05182073 ↗ |
| Modality | Cell therapy | “FT576 comprises allogeneic natural killer (NK) cells” NCT05182073 ↗ |